2 recruiting, 1 active not recruiting, 1 completed, 1 not yet recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Neurofibromatosis Type 1 (NF1): new trials by email Literature Review of Neurofibromatosis Type 1 (NF1) trials Research Report on Neurofibromatosis Type 1 (NF1)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Observational Study of the Real-world Effectiveness and Safety of Selumetinib Treating Adult Patients With Neurofibromatosis Type 1 (NF1) Who Have Symptomatic, Inoperable Plexiform Neurofibroma (PN) Neurofibromatosis Type 1 (NF1) | Recruiting | AstraZeneca | 800 | 2026-09-28 | 2026-10-22 | |
| How Can the Experience of Hospital Outpatient Departments be Improved? Qualitative data collection activities - Neurofibromatosis Type 1 (NF1), NF2-related Schwannomatosis | Not yet recruiting | King's College London | 30 | 2026-09-01 | 2026-09-14 | |
| PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas PAS-004 Tablets - NF1 Mutation, Neurofibroma Plexiform | Phase 1 | Recruiting | Pasithea Therapeutics Corp. | 56 | 2025-05-30 | 2025-12-04 |
| MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Mirdametinib (PD-0325901) oral capsule or dispersible tablet - Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1) | Phase 2 | Active not recruiting | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 114 | 2019-09-29 | 2026-10-06 |
| Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1) Cholecalciferol - Neurofibromatosis Type 1 (NF1) | Phase 2 | Terminated | University of Utah | 26 | 2017-08-16 | 2022-05-25 |
| Precision Medicine for Neurocutaneous Syndromes in Western China Neurocutaneous Syndromes, Neurofibromatosis Type 1 (NF1) | Completed | West China Hospital | 1200 | 2000-01-01 | 2026-01-09 |
Neurofibromatosis 1 (6) · Neurofibromatoses (3) · Neurofibroma, Plexiform (2) · Hearing Loss (1) · Learning Disabilities (1) · Neurocutaneous Syndromes (1) · Neurofibroma (1) · Sturge-Weber Syndrome (1) · Tuberous Sclerosis (1) · Vision Disorders (1) · von Hippel-Lindau Disease (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (6) · Heredodegenerative Disorders, Nervous System (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Nerve Tissue (6) · Neoplastic Syndromes, Hereditary (6) · Nerve Sheath Neoplasms (6) · Nervous System Diseases (6) · Neurodegenerative Diseases (6) · Neuromuscular Diseases (6) · Peripheral Nervous System Diseases (6) · Neurocutaneous Syndromes (5) · Neurofibroma (5) · Neurofibromatoses (3)
Cholecalciferol (1) · Dietary Supplements (1) · Vitamin D (1) · mirdametinib (1)
AstraZeneca (1) · King's College London (1) · Pasithea Therapeutics Corp. (1) · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (1) · University of Utah (1) · West China Hospital (1)
United States (3) · China (2) · Australia (1) · Canada (1) · South Korea (1) · United Kingdom (1)
David H. Viskochil, MD, PhD (1) · Pinan Liu (1) · Sue Woodward, PhD (1) · Tiago R Marques, MD (1) · Zhichao Wang (1)